BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 2018;12:145-56. [PMID: 29028981 DOI: 10.1093/ecco-jcc/jjx133] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Weisshof R, Golan MA, Yvellez OV, Rubin DT. The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy 2018;10:837-49. [DOI: 10.2217/imt-2018-0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol 2019;12:1756284819848631. [PMID: 31205486 DOI: 10.1177/1756284819848631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
3 Nocerino A, Nguyen A, Agrawal M, Mone A, Lakhani K, Swaminath A. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. Adv Ther 2020;37:97-112. [PMID: 31760611 DOI: 10.1007/s12325-019-01151-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
4 Abdulrahim H, Sharlala H, Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis. Expert Opinion on Pharmacotherapy 2019;20:1953-60. [DOI: 10.1080/14656566.2019.1657404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Antonelli E, Torti G, Bassotti G. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.J Clin Gastroenterol. 2019;53:635-640. [PMID: 31373941 DOI: 10.1097/MCG.0000000000001250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochemical and Biophysical Research Communications 2018;507:330-6. [DOI: 10.1016/j.bbrc.2018.11.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
7 Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. Int J Colorectal Dis 2019;34:217-27. [PMID: 30564910 DOI: 10.1007/s00384-018-3218-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
8 Meddens CA, van der List ACJ, Nieuwenhuis EES, Mokry M. Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential. Gut 2019;68:928-41. [PMID: 30692146 DOI: 10.1136/gutjnl-2018-317516] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
9 Fernández-clotet A, Castro-poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Review of Clinical Immunology 2018;14:881-92. [DOI: 10.1080/1744666x.2018.1532291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100-111. [PMID: 30048708 DOI: 10.1016/j.pharmthera.2018.07.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
11 Alten R, Mischkewitz M, Stefanski A, Dörner T. Januskinase-Inhibitoren: State of the Art im klinischen Einsatz und Zukunftsperspektiven. Z Rheumatol 2020;79:241-54. [DOI: 10.1007/s00393-020-00768-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rosenberg J, Steinberg JM, Mattar MC. Tofacitinib for the treatment of ulcerative colitis: A review of the literature. World J Meta-Anal 2019; 7(8): 373-379 [DOI: 10.13105/wjma.v7.i8.373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
16 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
18 Gerlach K, Lechner K, Popp V, Offensperger L, Zundler S, Wiendl M, Becker E, Atreya R, Rath T, Neurath MF, Weigmann B. The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation. J Crohns Colitis 2020:jjaa162. [PMID: 32808031 DOI: 10.1093/ecco-jcc/jjaa162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Palasik BN, Wang H. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. J Pharm Pract 2020;:897190020953019. [PMID: 32873116 DOI: 10.1177/0897190020953019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Panés J, Gisbert JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019;42:403-12. [DOI: 10.1016/j.gastrohep.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Serra López-matencio JM, Morell Baladrón A, Castañeda S. Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica 2019;152:353-60. [DOI: 10.1016/j.medcli.2018.10.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panés J. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. Inflamm Bowel Dis 2021;27:983-93. [PMID: 32794567 DOI: 10.1093/ibd/izaa193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. J Crohns Colitis 2020;14:S737-45. [PMID: 31879750 DOI: 10.1093/ecco-jcc/jjz202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019;58:i43-54. [PMID: 30806709 DOI: 10.1093/rheumatology/key276] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 46.0] [Reference Citation Analysis]
26 Serra López-matencio JM, Morell Baladrón A, Castañeda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica (English Edition) 2019;152:353-60. [DOI: 10.1016/j.medcle.2019.02.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yun Y, Chen J, Wang X, Li Y, Hu Z, Yang P, Qin L. Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway. Biomed Res Int 2021;2021:8877056. [PMID: 33511217 DOI: 10.1155/2021/8877056] [Reference Citation Analysis]
28 Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. Eur J Gastroenterol Hepatol 2020;32:669-77. [PMID: 32282548 DOI: 10.1097/MEG.0000000000001730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wei J, Ma L, Li C, Pierson CR, Finlay JL, Lin J. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. Curr Cancer Drug Targets 2019;19:571-82. [PMID: 30332965 DOI: 10.2174/1568009618666181016165604] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Venkateswaran N, Weismiller S, Clarke K. Indeterminate Colitis - Update on Treatment Options. J Inflamm Res 2021;14:6383-95. [PMID: 34876831 DOI: 10.2147/JIR.S268262] [Reference Citation Analysis]
31 Wilson L, Tuson S, Yang L, Loomes D. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2021;4:101-9. [PMID: 34056527 DOI: 10.1093/jcag/gwaa005] [Reference Citation Analysis]
32 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
33 Fernández-clotet A, Castro-poceiro J, Panés J. JAK Inhibition: The Most Promising Agents in the IBD Pipeline? CPD 2019;25:32-40. [DOI: 10.2174/1381612825666190405141410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
34 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Reference Citation Analysis]
35 Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, Singh E, Sunna N, Tarcha N, Mosli M. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Expert Rev Gastroenterol Hepatol. 2018;12:883-897. [PMID: 30096985 DOI: 10.1080/17474124.2018.1503052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 T Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019;33:15-32. [PMID: 30701418 DOI: 10.1007/s40259-019-00333-w] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 25.3] [Reference Citation Analysis]
37 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Reference Citation Analysis]
39 Yankin AN, Dmitriev MV. Nickel complexes as efficient catalysts in multicomponent synthesis of tetrahydropyridine derivatives. Synthetic Communications 2020;50:3481-9. [DOI: 10.1080/00397911.2020.1803357] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
41 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020;25:E3321. [PMID: 32707925 DOI: 10.3390/molecules25153321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Lees CW, Deuring JJ, Chiorean M, Daperno M, Bonfanti G, Germino R, Brown PB, Modesto I, Edwards RA. Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. Therap Adv Gastroenterol 2021;14:17562848211054710. [PMID: 35154388 DOI: 10.1177/17562848211054710] [Reference Citation Analysis]
43 Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;1:CD012381. [PMID: 31984480 DOI: 10.1002/14651858.CD012381.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]